Catherine Isted
Appointed to role
September 2023.
Skills and experience
Catherine is an experienced strategic finance professional and chartered accountant with over 25 years within the life sciences industry. She was most recently chief executive officer of ReNeuron (AIM: RENE), a UK-based leader in stem cell-derived exosome technologies, having previously been chief financial officer. Prior to this, she was at Oxford Biomedica plc (LSE: OXB), a quality and innovation-led viral vector Contract Development and Manufacturing Organization (CDMO), at a time of significant growth for the company, where as part of the finance leadership team, she headed up corporate development and investor relations as well as worked with the board on various strategic projects.
Previously Catherine had a successful career in leading healthcare banking teams, twelve years of which were at partner level, holding research analyst and equity sales positions at Morgan Stanley, ABN AMRO, Nomura and Peel Hunt. She started her career as a bench scientist at Merck Sharp & Dohme (MSD), before moving into their finance department as an accountant. Catherine holds a first-class chemistry degree and is a qualified Chartered Management Accountant.